Sign in to view content

First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability

Pravin U. Dugel, MD

Video
Published 2019

Pravin U. Dugel, MD

AMD Neovascular Part II Symposium

Related

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019

Category: AMD-Neovascular

See more